Answers are grounded in this paper and cite their sources.
Engineering a hyaluronic acid–functionalized graphene oxide platform improves doxorubicin sensitivity in drug-resistant cells, suggesting a novel cancer therapy approach.
Multidrug resistance (MDR) significantly limits breast cancer chemotherapy effectiveness. Here, we engineered a hyaluronic acid–functionalized graphene oxide (HA‐GO) nanocarrier for co‐delivery of microRNA‐489 and MDR1 antisense oligonucleotide (ASO, MB1) alongside doxorubicin (DOX). Among various nucleic acid ratios, a MiR‐489:MDR1 ASO ratio of 2:1 exhibited the most potent enhancement of DOX sensitivity in MCF‐7/ADM cells. This co‐delivery system synergistically reduced drug resistance, increased intracellular DOX accumulation, and amplified cytotoxicity. These results highlight the optimized HA‐GO platform as a promising strategy to overcome MDR in breast cancer therapy.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: